BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 15179004)

  • 21. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement.
    Martín G; Barragán E; Bolufer P; Chillón C; García-Sanz R; Gómez T; Brunet S; González M; Sanz MA
    Haematologica; 2000 Jul; 85(7):699-703. PubMed ID: 10897121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
    Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
    Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
    Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
    Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
    Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The significance of minimal residual disease in patients with t(15;17).
    Grimwade D
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):137-58. PubMed ID: 11987921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
    Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A; Gillis D; Lewis I
    Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
    Corbacioglu A; Scholl C; Schlenk RF; Eiwen K; Du J; Bullinger L; Fröhling S; Reimer P; Rummel M; Derigs HG; Nachbaur D; Krauter J; Ganser A; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(23):3724-9. PubMed ID: 20625124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of minimal residual disease in acute leukemia patients.
    van Dongen JJ; Szczepański T; de Bruijn MA; van den Beemd MW; de Bruin-Versteeg S; Wijkhuijs JM; Tibbe GJ; van Gastel-Mol EJ; Groeneveld K; Hooijkaas H
    Cytokines Mol Ther; 1996 Jun; 2(2):121-33. PubMed ID: 9384697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring of minimal residual disease in acute myeloid leukemia.
    Kern W; Schoch C; Haferlach T; Schnittger S
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):283-309. PubMed ID: 16213150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
    Lapillonne H; Renneville A; Auvrignon A; Flamant C; Blaise A; Perot C; Lai JL; Ballerini P; Mazingue F; Fasola S; Dehée A; Bellman F; Adam M; Labopin M; Douay L; Leverger G; Preudhomme C; Landman-Parker J
    J Clin Oncol; 2006 Apr; 24(10):1507-15. PubMed ID: 16575000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Introducing minimal residual disease in acute myeloid leukemia.
    Ofran Y; Rowe JM
    Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Genotyping and minimal residual disease study in children with acute myeloid leukemia: preliminary results].
    Balwierz W; Pietrzyk JJ; Wator G; Stozek K; Klekawka T; Kwiecińska K; Dłuzniewska A; Matysiak M; Malinowska I; Sikorska-Fic B; Balcerska A; Maciejka-Kapuścińska L; Sońta-Jakimczyk D; Tomaszewska R; Chybicka A; Krawczuk-Rybak M; Muszyńska-Rosłan K; Młynarski W; Stolarska M; Urasiński T; Kamieńska E; Sobol G; Wieczorek M; Karolczyk G; Wysocki M; Kołtan S; Kowalczyk JR; Wójcik B; Ksiazek T; Szewczyk K
    Przegl Lek; 2010; 67(6):371-4. PubMed ID: 21344764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of multiparameter flow cytometry for disease monitoring in AML.
    Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T
    Best Pract Res Clin Haematol; 2010 Sep; 23(3):379-90. PubMed ID: 21112037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal residual disease in acute myeloid leukaemia.
    Liu Yin JA
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):119-35. PubMed ID: 11987920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.
    Schnittger S; Schoch C; Kern W; Hiddemann W; Haferlach T
    Acta Haematol; 2004; 112(1-2):68-78. PubMed ID: 15179006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.